sutimlimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5512	2049079-64-1

Description:

Molecule	Description
Molfile Synonyms: sutimlimab sutimlimab-jome enjaymo TNT009 BIVV009 sutimlimab (genetical recombination)	Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

sutimlimab
sutimlimab-jome
enjaymo
TNT009
BIVV009
sutimlimab (genetical recombination)

Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Nov. 15, 2022	EMA	GENZYME EUROPE BV
Feb. 4, 2022	FDA	BIOVERATIV THERAPEUTICS INC
June 20, 2022	PMDA	SANOFI K.K

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA55	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA MoA	N0000193990	Classical Complement Pathway Inhibitors
FDA EPC	N0000193991	Classical Complement Pathway Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cold autoimmune hemolytic anemia	indication	398937006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Complement C1s subcomponent	Enzyme	P09871	C1S_HUMAN	INHIBITOR	Kd	9.59		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4297832	ChEMBL_ID
C000634098	MESH_SUPPLEMENTAL_RECORD_UI
C000623343	MESH_SUPPLEMENTAL_RECORD_UI
9807	IUPHAR_LIGAND_ID
DB14996	DRUGBANK_ID
018948	NDDF
4041155	VANDF
4041156	VANDF
C4727016	UMLSCUI
D11530	KEGG_DRUG
10737	INN_ID
2591404	RXNORM
356904	MMSL
40469	MMSL
d09855	MMSL
GNWE7KJ995	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Enjaymo jome	HUMAN PRESCRIPTION DRUG LABEL	1	80203-347	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	BLA	28 sections
Enjaymo jome	HUMAN PRESCRIPTION DRUG LABEL	1	80203-347	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	BLA	28 sections
Enjaymo jome	HUMAN PRESCRIPTION DRUG LABEL	1	80203-347	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	BLA	28 sections